Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 133


A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.

Correa RJM, Ahmad B, Warner A, Johnson C, MacKenzie MJ, Pautler SE, Bauman GS, Rodrigues GB, Louie AV.

Radiat Oncol. 2018 Mar 20;13(1):47. doi: 10.1186/s13014-018-0992-3.


The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma.

Punjani N, Clark R, Izawa J, Chin J, Pautler SE, Power N.

Can Urol Assoc J. 2017 Dec 22. doi: 10.5489/cuaj.4650. [Epub ahead of print]


Vision-Based Surgical Field Defogging.

Luo X, McLeod AJ, Pautler SE, Schlachta CM, Peters TM.

IEEE Trans Med Imaging. 2017 Oct;36(10):2021-2030. doi: 10.1109/TMI.2017.2701861. Epub 2017 May 11.


The Impact of Multiple Prostate Biopsies on Risk for Major Complications Following Radical Prostatectomy: A Population-based Cohort Study.

Olvera-Posada D, Welk B, McClure JA, Winick-Ng J, Izawa JI, Pautler SE.

Urology. 2017 Aug;106:125-132. doi: 10.1016/j.urology.2017.03.048. Epub 2017 Apr 21.


Structured assessment and followup for patients with hereditary kidney tumour syndromes.

Lattouf JB, Pautler SE, Reaume MN, Kim RH, Care M, Green J, So A, Violette PD, Saliba I, Major P, Silver S, Leicht R, Basiuk J, Tanguay S, Jewett MA, Drachenberg D; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E214-E222. doi: 10.5489/cuaj.3798. Epub 2016 Jul 12. Erratum in: Can Urol Assoc J. 2017 Aug;11(8):E325.


KIM-1 Is a Potential Urinary Biomarker of Obstruction: Results from a Prospective Cohort Study.

Olvera-Posada D, Dayarathna T, Dion M, Alenezi H, Sener A, Denstedt JD, Pautler SE, Razvi H.

J Endourol. 2017 Feb;31(2):111-118. doi: 10.1089/end.2016.0215. Epub 2016 Dec 19.


Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer.

Forbes CM, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lacombe L, Kawakami J, Drachenberg DE, Pautler SE, Jewett MMA, Saarela O, Liu Z, Tanguay S, Black PC.

Urol Oncol. 2016 Nov;34(11):486.e17-486.e23. doi: 10.1016/j.urolonc.2016.05.034. Epub 2016 Jul 14.


Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion.

Gibson E, Bauman GS, Romagnoli C, Cool DW, Bastian-Jordan M, Kassam Z, Gaed M, Moussa M, Gómez JA, Pautler SE, Chin JL, Crukley C, Haider MA, Fenster A, Ward AD.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):188-96. doi: 10.1016/j.ijrobp.2016.04.018. Epub 2016 Apr 21.


Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis JL, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Am J Ophthalmol. 2016 Apr;164:29-36. doi: 10.1016/j.ajo.2015.12.028. Epub 2015 Dec 31.


Independent predictors of prolonged operative time during robotic-assisted radical prostatectomy.

Violette PD, Mikhail D, Pond GR, Pautler SE.

J Robot Surg. 2015 Jun;9(2):117-23. doi: 10.1007/s11701-015-0497-0. Epub 2015 Feb 12.


Re: Saksens et al.: Dominant cystoid macular dystrophy (Ophthalmology 2015;122:180-91).

Pautler SE, Browning DJ.

Ophthalmology. 2015 Oct;122(10):e59-60. doi: 10.1016/j.ophtha.2015.02.042. No abstract available.


Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Am J Ophthalmol. 2015 Dec;160(6):1133-1141.e9. doi: 10.1016/j.ajo.2015.09.017. Epub 2015 Sep 18.


Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.

Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group.

Ophthalmology. 2015 Nov;122(11):2351-9. doi: 10.1016/j.ophtha.2015.07.036. Epub 2015 Sep 7.


Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE.

Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20.


Quality of life after radical prostatectomy: Continuing to improve on our track record.

Chan G, Pautler SE.

Can Urol Assoc J. 2015 May-Jun;9(5-6):188-9. doi: 10.5489/cuaj.2999. No abstract available.


Re: Impact of Macula-off Retinal Detachment on Visual Outcome, A Systematic Review and Meta-Analysis of Literature.

Browning DJ, Pautler SE, Wong KL, Telander DG, Stewart MW.

Retina. 2015 Jul;35(7):e44. doi: 10.1097/IAE.0000000000000673. No abstract available.


Surgical management of stage T1 renal tumours at Canadian academic centres.

Lavallée LT, Tanguay S, Jewett MA, Wood L, Kapoor A, Rendon RA, Moore RB, Lacombe L, Kawakami J, Pautler SE, Drachenberg DE, Black PC, Lattouf JB, Morash C, Cagiannos I, Liu Z, Breau RH.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):99-106. doi: 10.5489/cuaj.2598. Erratum in: Can Urol Assoc J. 2016 Aug;10 (7-8):E281.


Re: Pachychoroid neovasculopathy.

Pautler SE, Browning DJ.

Retina. 2015 Jul;35(7):e39-40. doi: 10.1097/IAE.0000000000000661. No abstract available.


Near-infrared reflectance bull's eye maculopathy as an early indication of hydroxychloroquine toxicity.

Wong KL, Pautler SE, Browning DJ.

Clin Ophthalmol. 2015 Mar 19;9:521-5. doi: 10.2147/OPTH.S76963. eCollection 2015.

Supplemental Content

Loading ...
Support Center